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Abstract
Introduction: As highly active antiretroviral therapy (HAART) transforms human immunodeficiency virus (HIV) into a manageable
chronic disease, new challenges are emerging in treating children born with HIV, including a number of risks to their physical and
psychological health due to HIV infection and its lifelong treatment.
Methods: We conducted a literature review to evaluate the evidence on the physical and psychological effects of perinatal HIV
(PHIV ) infection and its treatment in the era of HAART, including major chronic comorbidities.
Results and discussion: Perinatally infected children face concerning levels of treatment failure and drug resistance, which may
hamper their long-term treatment and result in more significant comorbidities. Physical complications from PHIV infection
and treatment potentially affect all major organ systems. Although treatment with antiretroviral (ARV) therapy has reduced
incidence of severe neurocognitive diseases like HIV encephalopathy, perinatally infected children may experience less severe
neurocognitive complications related to HIV disease and ARV neurotoxicity. Major metabolic complications include dyslipidaemia
and insulin resistance, complications that are associated with both HIV infection and several ARV agents and may significantly
affect cardiovascular disease risk with age. Bone abnormalities, particularly amongst children treated with tenofovir, are a
concern for perinatally infected children who may be at higher risk for bone fractures and osteoporosis. In many studies, rates of
anaemia are significantly higher for HIV-infected children. Renal failure is a significant complication and cause of death amongst
perinatally infected children, while new data on sexual and reproductive health suggest that sexually transmitted infections and
birth complications may be additional concerns for perinatally infected children in adolescence. Finally, perinatally infected
children may face psychological challenges, including higher rates of mental health and behavioural disorders. Existing studies
have significant methodological limitations, including small sample sizes, inappropriate control groups and heterogeneous
definitions, to name a few.
Conclusions: Success in treating perinatally HIV-infected children and better understanding of the physical and psychological
implications of lifelong HIV infection require that we address a new set of challenges for children. A better understanding of
these challenges will guide care providers, researchers and policymakers towards more effective HIV care management for
perinatally infected children and their transition to adulthood.
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Introduction
An estimated 3.2 million children currently live with human
immunodeficiency virus (HIV) [1]. Children with perinatal HIV
infection (PHIV ) in the era of highly active antiretroviral
therapy (HAART) have significantly improved odds of survival
compared to the pre-HAART era [2] and are living into ado-
lescence and adulthood in unprecedented numbers [3,4].
In the United States, mortality amongst HIV-infected children
declined from 7.2 per 100 child-years in 1994 to 0.6 per 100
child-years in 2006, a more than 90% reduction [5]. Similar
achievements have been made in Europe [6]. In these
resource-rich settings, PHIV live longer, and fewer die of
opportunistic infections [7], but PHIV still face significantly
higher odds of morbidity and mortality compared to their
uninfected peers [8,9]. Overall, it is estimated that HIV-
infected children have mortality rates 30 times higher than
uninfected children of similar age in the United States [10].
Although deaths from opportunistic infections have decreased
significantly, deaths from end-stage, acquired immunodefi-
ciency syndrome (AIDS), sepsis and renal failure are now
more common [10]. And as HIV infection transforms from
a terminal illness to a chronic disease, new comorbidities
emerge, including metabolic disorders and cardiovascular
and kidney diseases [11]. These comorbidities represent sig-
nificant challenges to the long-term treatment and survival of
PHIV.
More than 90% of the world’s PHIV live in resource-
limited settings (RLS) such as sub-Saharan Africa (SSA), where
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less than a quarter of infected children currently receive
HAART [12] and HIV/AIDS is still a leading cause of childhood
and adolescent mortality [13]. In 2014, UNAIDS and partner
stakeholders released ambitious new targets for the scale up
of HIV testing and treatment, known as ‘‘90-90-90.’’ The aim
is that by 2020, 90% of HIV-infected individuals will know
their HIV status, 90% of diagnosed HIV-infected individuals
will receive HAART, and 90% of HIV-infected individuals on
HAART will be virally suppressed [14]. In addition, the 2013
World Health Organization (WHO) Consolidated ARV Guide-
lines recommend HAART for all PHIV under five years of age
regardless of clinical or immunological stage [15]. The push
towards these targets means that hundreds of thousands of
PHIV will initiate life-long HAART over the next decade.
Although the majority of these children will be living in
RLS, the experiences of PHIV in resource-rich settings, who
have been treated with HAART for many more years, offer
an important window into the long-term impact of perinatal
infection and lifelong treatment across all settings. The objec-
tive of this review is to summarize and evaluate current evi-
dence on the physical and psychological effects of PHIV
infection and its treatment in the HAART era, including major
chronic comorbidities. Insights will be offered on persistent
and emerging challenges in the field of PHIV and future direc-
tions for research. Although much of the literature in this
field comes from resource-rich settings, we will attempt to
give appropriate attention to issues affecting PHIV in SSA.
Methods
We conducted an extensive, literature review on the physical
and psychological effects of PHIV infection and its treat-
ment in the HAART era, including major chronic comorbid-
ities. Our methodology for this review was guided by Grant
and Booth [16] and their definition of a ‘‘literature review.’’
We searched major scientific literature databases (e.g.
PubMed, EMBASE and MEDLINE) between 1 February 2015
and 1 June 2015, and we used relevant keywords to guide
searches for appropriate sources. In this review, we aim to
present findings from major, landmark studies, as well as
from meta-analyses, systematic reviews and expert commen-
taries, to evaluate the current state of knowledge and to
identify research gaps on the physical and psychological
effects of PHIV infection. Where appropriate, we include
statistics such as odds ratios (OR), hazard ratios (HR) and con-
fidence intervals (CI), amongst other statistics. To facilitate
our objective, we organized the Results and Discussion sec-
tion in the following way: first, we review the general virologic
and treatment outcomes of perinatally infected children,
then discuss physical effects using an organ systems per-
spective (birth and growth outcomes, neurological, cardio-
vascular, gastrointestinal, renal, haematological, metabolic,
musculoskeletal and reproductive), and end with a review of
psychological effects.
Results and discussion
Viral and treatment outcomes
Studies from North America and Europe suggest that PHIV
have lower probability of achieving both viral suppression
and long-term treatment success compared to adults [17,18].
Data from RLS are limited but suggest more similar outcomes
for children and adults. A recent, systematic review compiled
data from 30 studies on treatment failure amongst 3241
childrenB18 years of age on first-line HAART in RLS [19]. In
seven studies using a definition of treatment failure as a
viral load (VL) 400 copies/mL, a median of 36% of children
(range 13 to 71%) had failed first-line HAART [19]. Slightly
better outcomes were reported in a systematic review of 89
studies including 9794 adult patients from SSA, in which a
median of 28% had failed after one year [20]. Authors of both
systematic reviews cited major challenges in comparing data
across studies due to heterogeneous study designs, defini-
tions, methods and length of follow-up.
Inadequate viral suppression can lead to the development
of drug resistance in adults [2124] and in children [25,26].
Drug resistance amongst PHIV, who need lifelong therapy
beginning at birth, is particularly concerning for their long-
term outcomes. The challenges of lack of viral suppression
and developing drug resistance are magnified for PHIV in
RLS, where they often have limited access to adequate viral
monitoring and to second- and third-line HAART regimens.
Aggregated data reveal concerning rates of ARV resistance
amongst PHIV. Sigaloff et al. [19] reviewed data from 30
studies including 2258 HIV-infected children who had failed
their first-line HAART regimen and calculated that a pooled
proportion of 90% of children had a resistance-associated
mutation (95% CI 88 to 93%). In subgroup analyses of children
who failed treatment less than one year after HAART ini-
tiation, 76% (95% CI 69 to 83%) had at least one resistance-
associated mutation [19]. The authors did not investigate
differences in treatment failure or drug resistance by route of
infection (perinatal versus other), presumably because few
studies reported this information.
PHIV may be at higher risk for treatment failure and drug
resistance for several reasons. First, PHIV may be exposed
to HAART in utero or during breastfeeding for (unsuccessful)
prevention of mother-to-child transmission (PMTCT) [27]. In
the United States, the widespread use of HAART for PMTCT
has reduced mother-to-child transmission to around 2% [28].
Despite its effectiveness, access, retention and adherence
to PMTCT are not adequate and may be especially difficult
in resource-poor settings [29,30]. Second, the risk of drug
resistance is higher for many older PHIV with complicated
treatment histories of monotherapy or dual therapy before
the advent of HAART [31]. Third, studies show that significant
proportions of PHIV have less than optimal therapeutic drug
levels [3235]. Subtherapeutic drug levels may be too low
for viral suppression, yet sufficient to exert selection pres-
sure that facilitates resistance mutation evolution [3640].
Although non-adherence is a significant cause of subther-
apeutic drug levels (see next section), even PHIV with high
levels of adherence can fail treatment and develop drug
resistance, particularly with longer treatment durations [41].
Conversely, supratherapeutic drug concentrations can also be
problematic and can lead to drug toxicities, more severe side
effects and non-adherence. Limited paediatric formulations,
variable pharmacokinetics (PK) and dosing data, and frequent
changes in dosing across the developmental course likely
contribute to inadequate treatment of PHIV, but more
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data are needed to address these challenges [42,43]. Finally,
PHIV are a unique cohort; they acquire HIV before the
maturation of their immune and organ systems and grow up
with early and lifelong exposure to HAART [44].
Closely linked to the treatment outcomes for PHIV is the
issue of medication adherence. Adherence to HAART is the
critical behaviour underlying many of the long-term out-
comes for children and adolescents with HIV. Systematic
reviews of PHIV adherence to HAART have reported widely
variable adherence estimates, likely due to heterogeneous
measurement techniques [43,45]. Three studies (one in the
United States and two in SSA) using electronic dose monitors,
typically considered the gold standard measure [4648],
showed high rates of median adherence amongst PHIV (81,
95 and 96% of doses taken) [46,49,50]. Although high median
rates of adherence are encouraging, they may not tell the
whole story; patterns of adherence behaviour may critically
shape outcomes. In the study from Kenya, only 68% of 191
PHIV achieved at least 90% adherence and they had a
median of three treatment interruptions of greater than
48hours over six months [50]. Another study in Kenya amongst
a cohort of 21 PHIV, established PK parameters for nevirapine
(NVP) and used electronic dose monitors to calculate that
almost half of the children spent more than 10% of time
below the minimum effective drug concentration over four
months of follow-up [51]. Although we know that non-
adherence and clinical outcomes such as treatment failure
are strongly associated [52,53], we lack data to characterize
fully the relationship between adherence and drug resis-
tance, particularly for PHIV in SSA. The risks of resistance
resulting from non-adherence may vary based on regimen
class, specific adherence patterns (e.g. treatment interrup-
tions versus sporadic missed doses) and host genomics, in
addition to the paediatric-specific factors just described [54].
Moreover, there are few data to inform strategies to improve
and sustain high levels of adherence and prevent drug resis-
tance in PHIV [43,55]. Studies do suggest that adherence
and viral suppression decrease as PHIV transition into
adolescence, highlighting the need for adherence interven-
tions during this time [5658].
It is in the context of these unique viral and treatment
challenges that we must consider the impact of the physical
and psychological effects of lifelong HIV infection, HAART
treatment and comorbidities over the developmental course.
Emerging data in these areas will be the focus of the remainder
of this review.
Birth outcomes
Fostering the growth of PHIV remains a major challenge
throughout the developmental spectrum, from the prenatal
to the adolescent phase. Although stillbirth, preterm birth
and low birthweight have declined significantly in the era
of PMTCT and HAART in resource-rich settings [59], several
studies found increased risk of preterm delivery with maternal
HAART use (versus mono or dual therapy for PMTCT), espe-
cially with protease inhibitor (PI)-containing regimens [6064].
Data from SSA in this area are sparse [65]. A meta-analysis of
studies conducted before 2007 found no overall link between
HAART use during pregnancy and increased risk for preterm
birth, but reported a significant association between PI-
containing regimens and preterm birth versus non-PI contain-
ing regimens (OR 1.4, 95% CI 1.1 to 1.7), as well as maternal
HAART started before pregnancy or in the first trimester
versus later in pregnancy (OR 1.7, 95% CI 1.1 to 2.7) [66].
More recent results from a study amongst a large, well
defined national cohort, the French Perinatal Cohort, found
that ritonavir-boosted PI regimens were associated with an
increased probability of preterm birth compared with non-
boosted PI regimens (adjusted HR 2.0) when controlling for
factors known to be associated with preterm delivery [67].
Preterm infants are at a significantly higher risk for a range of
complications, including respiratory problems, infections, dis-
ability and mortality, and these risks may be compounded for
PHIV [68]. More data are needed, particularly from SSA where
the vast majority of HIV-positive women reside, health sys-
tems are less capable of caring for preterm infants, and where
preterm delivery rates are the highest in the world [69].
Growth and development
Throughout childhood, PHIV tend to have shorter stature,
lower bodyweight and delayed entrance into puberty com-
pared to uninfected children, even in the absence of overt
AIDS or wasting [70]. This abnormal growth is associated with
a wide set of factors, including viraemia, symptomatic HIV
infection, malabsorption, inflammation, mitochondrial toxi-
city, psychosocial factors, micronutrient deficiency, abnormal
nitrogen balance, and impaired growth hormone secretion or
action [70]. A study using two large US longitudinal cohorts
between 2000 and 2012 found that the timing of pubertal
onset (Tanner stage]2) was significantly later for 2086 PHIV
compared to 453 HIV-exposed uninfected children [71]. Amongst
PHIV, the study also found that higher VL and lower CD4%
were associated with more delayed pubertal onset, and that
increased duration on HAART was associated with slightly
more normal pubertal onset [71]. These data suggest that
early access to HAART leads to more normal growth patterns
for PHIV, but there are few data from SSA where children
are more likely to be malnourished and suffer from other
diseases that are associated with poor growth [72].
Neurological outcomes
The incidence of severe, AIDS-defining neurocognitive dis-
eases, such as HIV encephalopathy, has significantly declined
in the HAART era [73,74]. Amongst 2398 PHIV in the US-
based Pediatric AIDS Clinical Trials Group (PACTG) 219/
219C cohorts followed from 1993 to 2007, incidence of HIV
encephalopathy decreased 10-fold beginning in 1996 (corre-
sponding to the rollout of HAART), with stable incidence rates
since 2002 at around two cases per 1000 person-years [75].
Nonetheless, PHIV on HAARTmay experience less severe
neurocognitive complications, including deficits in general
cognition, language and speech, gross motor, and fine motor
functioning, which can substantially affect their quality of life,
social relationships, school achievements and risk behaviours
[7681]. Several potential mechanisms for cognitive impair-
ment in PHIV on HAART have been proposed, including (1)
irreversible pre-HAART neuronal injury; (2) neuronal injury
from inflammatory responses and neurotoxic viral proteins;
(3) poor central nervous system (CNS) penetration of ARVs
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resulting in ongoing CNS viral replication and (4) neurotoxic
effects of ARVs [8286].
A number of studies reported that HIV-infected children
treated with HAART had lower neurocognitive scores, high
rates of motor deficits and delayed development compared
to uninfected peers [8795]; however, many of these studies
were hampered by small sample sizes, lack of adequate con-
trol groups and lack of control for disease severity [86].
Several recent studies provided evidence for the protective
effects of early HAART and viral suppression on neurodeve-
lopment in PHIV [96,97]. A prospective study amongst 90
PHIV South African children randomized to receive early
versus deferred HAART found significantly better neurode-
velopment outcomes at 11 months of age as measured by
the Griffiths Mental Development Scales in the early treat-
ment group, who had a mean age of ART initiation at 8.4
weeks versus 31.4 weeks for the deferred treatment group
[96]. Mental development scores from PHIV in the early
treatment group were comparable with scores from HIV-
uninfected (both exposed and unexposed) controls [96].
A study amongst 396 PHIV (mean age 9.6 years) in the
United States found that early viral suppression (at five years
of age or younger) was associated with higher cognitive
scores on the Wechsler intelligence scales [97]. The study
also found stronger associations in later birth cohorts when
HAART use was more widespread, suggesting that HAART
may improve neurocognitive outcomes independent of viral
suppression [97]. In contrast, a study of 284 Thai and Cambodian
PHIV aged 1 to 12 years in the PREDICT trial who were
randomized to early or deferred HAART initiation reported no
differences in neurodevelopmental scores between the two
groups after 144 weeks, and found both early and deferred
groups performed worse than uninfected controls [98,99].
However, the median age of HAART initiation was 6.4 years
for the early group  significantly later than HAART initiation
in the South Africa and US studies  which supports that
neurological protective effects may be most significant in
infancy and early childhood [98].
The potential effects of ARV-related neurotoxicity on neuro-
development amongst PHIV are not clear and must be
weighed against the benefits of CNS viral control. Cognitive
impairment and decline in PHIV on HAART with good im-
munologic and systemic viral control [85] may point to a lack
of CNS viral suppression due to poor drug CNS penetration,
CNS-resistant virus, persistent immune activation or un-
known factors [86]. Complicating this issue, ARVs that have
high CNS penetration may better control HIV replication in
cerebral spinal fluid that is associated with progressive HIV
disease and neurocognitive deficits [100,101]. At the same
time, ARVs with high CNS penetration may also increase the
risks of ARV-related neurotoxicity. There are too few data
amongst PHIV to assess the relationship between the level
of CNS penetration by HAART agents and neurocognitive
outcomes [74,75,97], and data amongst adults are conflicting
[102106].
A better understanding of the role of HIV infection and
HAART on neurocognitive outcomes is needed to optimize
treatment and to support the development of PHIV through
adolescence and into adulthood. The field particularly lacks
data from PHIV in SSA and data on how HIV infection and
HAART exposure in utero affect neurocognitive development,
as well as how these effects might be mitigated. Although
studies advocate for the protective effects of HAART early
in infancy [96,97], which is consistent with current WHO
guidelines [15], whether these benefits will persist through
adolescence and adulthood remains to be seen. More data
from well-designed, longitudinal studies are warranted, in
combination with measurement instruments adapted for
children in SSA settings. This should be a high-priority re-
search area as access to PMTCT and HAART expands, par-
ticularly in SSA.
Cardiovascular system
The cardiovascular complications of HIV infection were noted
early in the epidemic [107]. Current evidence suggests that
PHIV may be at increased cardiac risk due to viral mech-
anisms [108], exposure to HAART for treatment or in utero
for PMTCT or some combination [109]. Potential mechanisms
of HIV-associated cardiomyopathy include direct infection
of cardiac myocytes [107,110,111], increased production of
certain cytokines within the myocardium [112114] and nu-
cleoside reverse transcriptase inhibitor (NRTI)-induced mito-
chondrial toxicity [115117] that is most associated with
zalcitabine, didanosine (ddI), stavudine (d4T) and zidovudine
(AZT) [118122]. The P2C2 study was the first major cohort
study of PHIV to investigate cardiac complications and
found high five-year cumulative incidence rates of depressed
shortening fraction (28%), left ventricular end-diastolic dila-
tion (22%), and heart failure or need for cardiac medications
(29%); however, PHIV in this cohort had little exposure to
modern HAART regimens [123,124].
More recent data suggest largely protective cardiac effects
from HAART, especially early in life. In the largest prospec-
tive cohort study to date, 3035 PHIV enrolled in PACTG
219/219C were followed from 1993 to 2007 and showed that
the use of HAART (versus no HAART) dramatically lowered
incidence rates (by an average of 50%) of cardiomyopathy
[125]. In subanalyses amongst HAART users, older age at
HAART initiation, nadir CD4% below 15%, and initiating an
AZT-containing regimen were independently associated with
an increased risk of cardiomyopathy [125]. In another well-
designed study, 70 PHIV from the earlier P2C2 study who
had little exposure to HAART had significantly lower (i.e. worse)
z-scores for left ventricular fractional shortening at around
age 10 compared to 325 PHIV from the AMP cohort who
had widespread use of HAART (pB0.05) [126]. Longer ARV
exposure and lower nadir CD4% were associated with lower
mean left ventricular fractional shortening z-scores in PHIV
from the P2C2 cohort but not from the AMP cohort, sug-
gesting that cardiac damage was more significant for PHIV
early in life who did not receive effective HAART [126].
The effects of HAART exposure in utero are unclear, as
two major studies amongst ART- exposed uninfected infants
revealed conflicting results [127,128]. The CHAART-1 study
found evidence that foetal exposure to HAART was asso-
ciated with reduced left ventricular mass, left ventricular
dimension and septal wall thickness [127], whereas the larger
SMARTT study found low risk of overall cardiac anomalies and
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no specific increase in anomalies with any individual ARV
[128]. Studies in SSA are lacking and were mostly conducted
before widespread use of HAART [129131]. The long-
term effects of HAART exposure on PHIV in adolescence
and young adulthood are also unknown. A small study of 28
PHIV with a mean age of 18.0 years who had been on
HAART for a mean of 14.6 years found that although standard
echocardiographic measures were normal, there was evi-
dence of high impaired strain and strain rate (which have
been proposed as prognostic factors for long-term myocardial
dysfunction [132]) compared to age-matched, uninfected, un-
exposed controls [133]. The clinical impact of these changes
over time is not known.
Although cardiovascular complications have significantly
declined in the HAART era, PHIV still may be at higher risk
for cardiomyopathies. Further research is needed on the
long-term myocardial function of PHIV and on optimizing
HAART regimens to protect cardiac health and to effectively
suppress HIV replication. Close monitoring of cardiovascular
function for this population is warranted, as is surveillance
for HIV-uninfected children exposed to HAART in utero  a
population that will increase significantly in size with more
access to PMTCT under the 90-90-90 target.
Gastrointestinal system
A prominent area of concern is the impact of HIV infection and
its treatment on liver function for PHIV, though there are
few paediatric-specific data and long-term outcomes are
mostly extrapolated from adult data [134]. PHIV tend to
have HIV-associated elevated aspartate aminotransferase-to-
platelet ratio indices, which may indicate liver fibrosis [135,136].
There are more data on the impact of HAART on liver func-
tion, which must be closely monitored in PHIV. Almost all
ARVs  in particular, atazanavir, ddI, indinavir and NVP  have
the potential to cause hepatitis, hyperbilirubinaemia, liver
toxicity and liver dysfunction [137]. In a small study of 26
PHIV on HAART aged 8 to 18 years, more than half had bio-
logical and/or radiological signs of hepatic impact, which was
associated with older age, advanced disease stage and treat-
ment with NRTI- and non-nucleoside analogue reverse tran-
scriptase inhibitor (NNRTI)-containing regimens [138]. Regular
monitoring of the liver function of PHIV is critical, which is
now possible using various non-invasive procedures [138].
Co-infections can complicate treatment and increase the
risks for liver damage, as is seen amongst HIV-infected adults
with Hepatitis B virus (HBV) and Hepatitis C virus (HCV) co-
infection [139]. There are comparatively few data on HBV and
HCV co-infection amongst PHIV, but a small number of
studies suggest significant levels of chronic HBV and HCV co-
infection [140143]. Hepatitis co-infection requires specific
treatment to reduce the risks of liver disease, hepatic fibrosis
and cirrhosis in PHIV [144,145].
Renal system
Renal disease is a growing concern for PHIV [146], and now
accounts for 5% of mortality amongst PHIV in the HAART
era [10]. The risk of HIV-associated nephropathy (HIVAN)
has declined significantly with the rollout of HAART [147],
but there are chronic renal complications predicted by renal
abnormalities that may be caused by long-term HIV infection
[148,149] and exacerbated by nephrotoxic ARVs [150]. This
may be a particular concern with tenofovir disoproxil
fumarate (TDF)-containing regimens in PHIV, but study
findings are not consistent [151154]. The most common
histopathological abnormality identified in renal biopsies in
children with HIVAN is focal segmental glomerulosclerosis
[155]. Host genomics play a significant role in the develop-
ment of HIVAN, resulting in a fourfold increased risk for end-
stage, kidney disease in African Americans in the United States
[156,157]. High rates of renal disease amongst HIV-infected
adults have been reported in SSA, along with evidence of a
broader spectrum of histopathological lesions, but there are
few data amongst PHIV [158]. A retrospective analysis of
PHIV in the US-based PACTG 219/219C cohorts identified a
variety of immune complex-mediated glomerulonephritides
and HIVAN, with an incidence rate of chronic kidney disease
of 2.79 events per 1000 person years in the 2003 to 2006
HAART era [159]. Other longitudinal cohort studies in the
United States have found prevalence rates of nephrotic-range
proteinuria between 8 and 11% amongst PHIV on HAART,
with common risk factors of renal dysfunction including older
age, uncontrolled viraemia, AfricanAmerican race and use
of TDF-containing regimens [160,161].
There are few data on survival outcomes amongst PHIV
with end-stage kidney disease on maintenance dialysis in the
HAART era. Two small studies amongst HIV-infected children
with end-stage kidney disease on maintenance haemodialysis
in the United States reported high mortality associated with
cardiovascular disease, leading the authors to recommend
routine echocardiography amongst HIV-infected children on
dialysis [162,163]. Studies on kidney transplantation for
HIV-infected individuals on HAART with end-stage kidney
disease, once contraindicated in this population, show com-
parable three to five years survival rates to transplantation
in uninfected individuals [164166], but there are few data
amongst children. More longitudinal data are needed to
guide screening, prevention and treatment of renal diseases
amongst an aging PHIV cohort, particularly as kidney dis-
eases evolve from more acute conditions associated with
advanced HIV disease to chronic diseases associated with
long-term HIV infection and HAART exposure, as well as
potential metabolic disorders. For PHIV in SSA and other
RLS, interventions to prevent end-stage kidney disease are
especially urgent as access to dialysis and transplantation
are limited.
Haematological issues
A frequent complication of HIV infection is anaemia. HIV
infection may alter cytokine and erythropoietin responses by
decreasing erythropoiesis through apoptosis of erythroid
precursors and infection of auxiliary cells [167,168]. A number
of common co-infections in PHIV, such as neoplasms [169]
and bacterial and fungal infections [170172] including
mycobacterial infections (e.g. Mycobacterium tuberculosis)
[173,174], also increase risks for anaemia. In addition, children
with HIV are at greater risk for more severe malaria-related
anaemia compared to uninfected children [175,176]. Treat-
ment with HAART, especially with AZT-containing regimens,
is associated with increased risk for anaemia in children
Vreeman RC et al. Journal of the International AIDS Society 2015, 18(Suppl 6):20258
http://www.jiasociety.org/index.php/jias/article/view/20258 | http://dx.doi.org/10.7448/IAS.18.7.20258
5
[177179], including at birth for PHIV whose mothers were
taking AZT for PMTCT [180,181]. A systematic review of 36
studies found that PHIV compared to uninfected children
were at significantly higher odds of anaemia, with a calculated
pooled random-effects OR of mild (haemoglobin B11 g/dL)
and moderate (haemoglobin B9 g/dL) anaemia of 4.5 (95%
CI 2.5 to 8.3) and 4.5 (95% CI 2.0 to 10.3), respectively, but
there were few data on severe anaemia (haemoglobinB7 g/dL)
[182]. Anaemia was commonly associated with HIV disease
progression and mortality, and the use of HAART and treat-
ment of secondary infections were protective, suggesting that
as more PHIV access HAARTand are able to switch regimens
when AZT-associated anaemia is suspected, severe anaemia-
related complications may be reduced in this population
[182].There is little evidence to support additional therapeutic
interventions for anaemia amongst PHIV, including inter-
ventions such as recombinant human erythropoietin and
micronutrient supplementation, and more data are needed to
evaluate these potential treatment options [183].
Metabolic impact
PHIV on HAART are at an increased risk for metabolic dis-
orders [184186]. Lipodystrophy syndrome (or ‘‘fat redis-
tribution’’) comprises both lipoatrophy (loss of subcutaneous
fat from the face, limbs and buttocks) and lipohypertrophy
(increase of central fat) and can occur independent of weight
change and dyslipidaemia [187]. HAART-associated lipoatro-
phy and lipohypertrophy have different and multifactorial
pathogeneses that may involve changes in genetic poly-
morphisms, lipid metabolism, and adipocyte and mitochon-
drial cell function [188,189]. Studies reported a prevalence
of lipodystrophy for PHIV on HAART between 10 and 33%
[190196], but rates as high as 57% have been found in
Europe [197,198] and 65% in Thailand [199]. Common risk
factors for lipodystrophy include longer duration on HAART,
older age (especially during puberty), more severe HIV dis-
ease, and regimens containing NRTIs (particularly d4T and
AZT) and to a lesser degree PIs, which may act synergistically
when used together [200,201].
Body fat changes may ultimately affect adherence to therapy
amongst older children and adolescents because they affect
body image and the social desire to fit in is a strong motivator
of behaviour during adolescent development [202]. In addition,
characteristic body fat changes associated with HIV treatment
may be recognizable and elicit HIV-related stigma, leading
to reduced quality of life and adherence to medications,
particularly in settings like SSA where HIV/AIDS stigma is per-
vasive [203205]. Proper management of HAART-associated fat
redistribution is critical in supporting the long-term treatment
of PHIV, particularly in SSAwhere fewer regimen options are
combined with higher risks of stigma.
Dyslipidaemia, including hypertriglyceridaemia (elevated
triglyceride levels) and hypercholesterolaemia (elevated LDL-
cholesterol levels), is another potential metabolic comp-
lication for PHIV on HAART [206]. Elucidating potential
mechanisms of dyslipidaemia in the HAART era have focused
on the impact of PIs on the inhibition of low-density lipo-
protein receptor-related proteins [207]. Data are limited to
mostly small studies from the United States and Europe,
where prevalence of hypertriglyceridaemia in PHIV on
HAART ranges from 13 to 67% [186,190,192,208211] and
hypercholesterolaemia from 10 to 68% [186,190,192,208
212]. In the largest study to date amongst 2122 PHIV in
the PACTG 219C cohort, the incidence rate for hypercholes-
terolaemia (total cholesterol ]220mg/dL at two consecutive
time points) was 3.4 cases per 100 person-years (95% CI 3.0 to
3.9) [213]. The most significant factors associated with the
development of hypercholesterolaemia after adjusting for
age were the use of PI-containing regimens and lower VL
[213]. In a follow-up study of the 240 PHIV who developed
hypercholesterolaemia, only 34% experienced resolution to
normal cholesterol levels after two years [214]. Smaller
studies have shown potential benefits from switching from a
PI-based to NNRTI-based regimen but more data are needed
to guide optimal treatment in PHIV [215218]. Further-
more, although the first-line treatment for dyslipidaemia in
children is to change the diet and increase physical exercise,
there are not data on the efficacy of these strategies amongst
PHIV on HAART, and there are not clear guidelines on lipid
thresholds for the use of statins and other lipid-lowering
medications in this population [219]. As more PHIV initiate
lifelong HAART, access to lipid monitoring needs to be
supported to reduce the potential for drug toxicity and long-
term lipid disorders.
Insulin resistance is characterized by reduced insulin stimu-
lation of glucose use by adipose tissue and muscles resulting
in increased pancreatic insulin production, and is associated
with obesity, dyslipidaemia, hypertension and type 2 diabetes
in children [220]. Both PIs and NRTIs are associated with
insulin resistance through inhibition of GLUT-4 transporters
in myocytes and adipocytes, causing decreased uptake of
glucose by these tissues [221,222]. HAART-associated body
composition changes such as central obesity, resulting in
fat deposition in muscle cells, may also contribute to insulin
resistance [223], but data are inconclusive [224,225]. The
prevalence of insulin resistance in PHIV varies widely, rang-
ing from 7 to 52% [190,208,209,211,226,227]. In 2011, a study
amongst a large cohort of 402 PHIV in the United States
found insulin resistance in 15% of the cohort, which was most
strongly associated with obesity but also with low CD4%
and exposure to PIs [228]. The prevalence of other glucose
metabolism disorders such as abnormal fasting glucose and
impaired glucose tolerance amongst PHIV is typically much
lower (below 7%), but studies are few and generally small
[186,190,208,209,211,227]. As in the case of dyslipidaemia,
treatment for insulin resistance includes diet and exercise, and
in the case of suspected PI-caused insulin resistance, studies
suggest improved insulin sensitivity with switches from a PI- to
NNRTI-based regimen in PHIV [229231].
PHIV are at an increased risk for a variety of metabolic
complications, but there are few longitudinal data to assess
incidence, risk factors and long-term outcomes of these meta-
bolic disorders [232]. Existing studies are further complicated
by small sample sizes, heterogeneous definitions and com-
plex interrelations in aetiology and risk factors. Metabolic
disorders are significant risk factors for the acceleration of
cardiovascular disease amongst HIV-infected adults [233], but
whether these complications lead to the same cardiovascular
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risks in the ageing PHIV cohort remains to be seen [234].
As PHIV enter adolescence and young adulthood, optimiz-
ing treatment and reducing HIV-related and non-HIV-related
risk factors for metabolic disorders are critical. Further
data to guide prevention, monitoring and management of
complications are urgently needed. PHIV in SSA may be
at increased risk of poor diagnosis and management of
complications due to lack of access to cardiac and metabolic
monitoring tools.
Musculoskeletal system
PHIV may be at greater risk for lower bone mineral density
(BMD) due to viral infection  by affecting BMD-related
growth factors [235,236]  and due to HAART exposure
[237,238], particularly TDF [239]. Recent studies amongst
PHIV revealed conflicting results. Two studies reported
significant BMD loss amongst children treated with TDF-
containing salvage regimens, with one-third losing more than
6% BMD [240,241]. It is unclear how these findings were
confounded by the children’s uncontrolled HIV infection,
although one study reported that two children who discon-
tinued TDF had significant recovery of BMD at 96 weeks [240].
Other studies found no association between TDF-containing
regimens and greater risk for lower BMD [218,242,243]. In the
longest study to date, 26 PHIV on TDF-containing regimens
were followed for 132 months and showed good viraemic
control and no significant increase in serum creatinine [244].
The effects of TDF may vary by developmental stage;
studies have reported that TDF-associated BMD loss is less
significant in adolescents and adults compared to PHIV in
pre- or early pubertal stages [245,246]. Younger children’s
BMD may be more affected because their skeletal growth
requires higher bone turnover; however, the aetiology, long-
term risks and consequences of lower BMD for PHIV are
not known [247]. More data are needed to guide optimal
treatment regimens and to identify potential long-term com-
plications of decreased BMD amongst PHIV, who may
consequently be at higher risk for bone fractures and oste-
oporosis later in life.
Sexual and reproductive health
Studies show that having a sexually transmitted infection
(STI) increases the risks for transmission and acquisition
of HIV [248,249], but whether HIV-infected individuals on
HAART with well-controlled HIV infection are at greater risk
for STIs is less clear [250,251]. Several studies reported high
rates of STIs amongst adolescents and young adults beha-
viourally infected with HIV [252256], but there are fewer
studies amongst PHIV. A study of 638 PHIV adolescent
women in the PACTG 219C cohort reported higher rates of
condylomata acuminata, trichomoniasis and cervical abnorm-
alities, including atypical cells, low-grade, squamous intrae-
pithelial lesions and high-grade squamous intraepithelial
lesions compared to matched, uninfected controls [257]. A
cohort study of PHIV and behaviourally infected women
in the United States found higher rates of pregnancy and
premature births in both groups compared to the general
population, with PHIV women significantly more likely to
electively terminate the pregnancy compared to behaviou-
rally infected women [258]. A recent retrospective cohort
study of 152 pregnancies in the United States reported that
uninfected infants born to PHIV mothers were significantly
shorter throughout the first year of life (after adjusting for
confounding) compared to uninfected infants born to non-
perinatally HIV-infected mothers [259], but the significance of
these findings is unclear.
There is limited evidence to inform sexual and reproduc-
tive interventions amongst PHIV. A recent systematic
review found evidence that linking sexual and reproductive
services with HIV/AIDS services resulted in improved out-
comes for women, including HIV and STI incidence, condom
use, contraceptive use and retention in care [260]. Effective
service delivery methods for sexual and reproductive health
care, in combination with adolescent care transitions [168,
261,262], must be investigated further as more PHIV enter
adolescence and adulthood. In addition, the seldom-discussed
issue of reproductive and sexual health for PHIV men will
need to be addressed.
Psychological health
A number of studies reported high rates of mental and
behavioural disorders amongst PHIV [92,263265]. Studies
in the United States found higher than expected rates of
anxiety, depression, hyperactivity, learning, other behavioural
problems amongst PHIV [92,263], as well as rates of psy-
chiatric hospitalizations three times higher compared to the
general paediatric population, most commonly for depres-
sion and behaviour disorders [264]. A review of eight studies
on the prevalence of psychiatric disorders amongst HIV-
infected children and youth (aged 4 to 21 years) using the
Diagnostic and Statistical Manual (Fourth Edition; DSM-IV)
found high rates of attention deficit/hyperactivity disorders
(29%), anxiety (24%) and depression (25%); however, the
authors noted the lackof control groups and small sample sizes
as significant limitations [265]. Several reviews have similarly
pointed to the methodological weaknesses in existing studies
on psychosocial outcomes amongst PHIV and the complex
interactions of genetic, social and environmental factors
[266,267]. Indeed, in larger, more well-designed trials with
appropriate control groups, studies reported less evidence for
increased mental and behavioural disorders amongst PHIV
in childhood or adolescence [263,268270]. In a US study,
the authors found that PHIV were no more likely to have
psychiatric symptoms than age-matched HIV-exposed unin-
fected controls, but were significantly more likely to be
diagnosed and to have received treatment for a psychiatric
disorder, including receiving psychotropic medication [268].
There is scarce evidence in the existing literature on
the specific role of HIV or HAART in affecting psychological
outcomes [267]. Several studies reported that low cognitive
functioning scores were associated with mental health dis-
orders amongst PHIV [92,98,271], but the significance of
this finding is not clear. Clinical disease markers such as AIDS
defining illness [272,273], higher VL [272,274] and low CD4
[272,275] were associated with mental and behavioural
disorders amongst PHIV in some studies, but not in others
[263,276,277]. There are also few data on psychological
outcomes amongst PHIV in RLS [278280]. High rates of
orphanhood amongst PHIV, particularly in SSA, may be an
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additional non-disease-related factor affecting mental and
behavioural health [281284]. Rigorous studies in settings
such as SSA are hampered by a lack of rigorously evaluated
and validated tools for assessing mental and behavioural
disorders in paediatric populations [285]. As hundreds of
thousands of PHIV transition into adolescence and adult-
hood, data are needed on the psychological challenges and
targeted mental and behavioural interventions for PHIV,
which are critical to support their long-term chronic disease
management [267].
Conclusions
The advent of HAART drastically changed the course of
HIV and significantly decreased HIV-associated morbidity
and mortality. Although HAART allows PHIV to survive
and prosper well into adolescence and adulthood, PHIV
still face many challenges related to their perinatal infection
and lifelong treatment. This review identified major chronic
complications and comorbidities affecting all major organ
systems. As more PHIV access HAART and live longer over
the next decades, data that improve the management and
ultimately prevention of these complications over the course
of the developmental spectrum are critical. For PHIV with
HIV-related disabilities, rehabilitation interventions are ne-
cessary to support their development with a chronic con-
dition, but there are few data in this area [286,287]. The
transition of PHIV from paediatric into adolescent and
adult care settings is another under-researched area with
significant implications for the treatment of long-term com-
plications and comorbidities in PHIV.
Many studies included in this review were conducted
in the United States and Europe. PHIV in resource-rich
settings represent an important population for study as they
are mostly older, have been treated with HAART for many
more years, and often initiated treatment at earlier ages
compared to PHIV in RLS. For these reasons, PHIV in
resource-rich settings offer critical insight into long-term
complications and comorbidities and interventions to im-
prove treatment and clinical outcomes. In addition, well-
established cohorts such as the PACTG 219/219C in the
United States provide opportunities to conduct studies with
relatively large sample sizes and close monitoring and follow-
up of patients. These cohorts have been particularly useful in
investigating complex effects on different organ systems from
HIV infection, HAART treatment or a combination of both. On
the other hand, we did identify a number of recent studies
from SSA, which is encouraging given that the region is home
to over 90% of PHIV in the world. Studies across regions,
both resource-rich and resource-poor, had significant limita-
tions, most often issues of sample size, appropriate control
groups, length of follow-up, heterogeneous definitions and
assessment methods, and unknown and complex interrela-
tions in aetiology and risk factors. Across all areas of research
identified in this review, more research is needed that uses
improved methodologies to address limitations. Establishing
well-characterized and closely followed cohorts of PHIV
in SSA and other RLS (as well as HIV-uninfected exposed
children) will be essential to answer important questions
around lifelong infection and treatment [288].
The combined evidence from this review supports the
protective effects of early HAART for PHIV against many
infection-related complications across organ systems; how-
ever, there are unanswered questions around HAART toxicity
and management of potential drug side effects, as well as
persisting infectious impacts. As the WHO guidelines advo-
cate for the treatment of all PHIV with HAART and we work
towards the goals of ‘‘90-90-90,’’ hundreds of thousands
of PHIV will be initiating early and lifelong HAART in the
coming years. HIV care programmes, particularly those in
SSA, will be tasked with huge challenges in expanding HAART
treatment and managing chronic complications and comor-
bidities of PHIV. Furthermore, persistent challenges in
areas such as infant diagnosis [289,290] and retention in care
[291], to name just a few, are additional barriers to effectively
treating PHIV in these settings. Finally, HIV cannot be
viewed as a problem only for the realm of infectious disease;
effective healthcare systems for the millions of youth need-
ing HIV treatment will incorporate a holistic approach to
the management of children and families’ physical, mental,
emotional, behavioural and social needs across the develop-
mental course.
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